Swing Therapeutics, a new San Francisco, CA-based digital therapeutics company, is taking a “swing” at fibromyalgia with an exclusive license from the university of Manitoba, a breakthrough device designation from FDA, VC funding, and the launch of a real-world study, MD+DI reports.
Swing launched with a $9 million seed investment from JAZZ Venture Partners.
Swing is one of a growing number of companies exploring the digital therapeutics market. The company’s real-world study is based on a clinically validated program that it licensed from the University of Manitoba. Swing’s program is designed to digitally deliver acceptance and commitment therapy, a form of cognitive behavioral therapy. Read more.
